Scientific publications

Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria

Jan 12, 2022 | Magazine: Science Translational Medicine

Karol M Córdoba 1 2, Irantzu Serrano-Mendioroz 1 2, Daniel Jericó 1 2, María Merino 3, Lei Jiang 4, Ana Sampedro 1 2, Manuel Alegre 5, Fernando Corrales 6, María J Garrido 3, Paolo G V Martini 4, José Luis Lanciego 2 7 8, Jesús Prieto 1, Pedro Berraondo 2 9 10, Antonio Fontanellas 1 2 11


Abstract

Correction of enzymatic deficits in hepatocytes by systemic administration of a recombinant protein is a desired therapeutic goal for hepatic enzymopenic disorders such as acute intermittent porphyria (AIP), an inherited porphobilinogen deaminase (PBGD) deficiency. Apolipoprotein A-I (ApoAI) is internalized into hepatocytes during the centripetal transport of cholesterol. Here, we generated a recombinant protein formed by linking ApoAI to the amino terminus of human PBGD (rhApoAI-PBGD) in an attempt to transfer PBGD into liver cells. In vivo experiments showed that, after intravenous injection, rhApoAI-PBGD circulates in blood incorporated into high-density lipoprotein (HDL), penetrates into hepatocytes, and crosses the blood-brain barrier, increasing PBGD activity in both the liver and brain.

Consistently, the intravenous administration of rhApoAI-PBGD or the hyperfunctional rApoAI-PBGD-I129M/N340S (rApoAI-PBGDms) variant efficiently prevented and abrogated phenobarbital-induced acute attacks in a mouse model of AIP. One month after a single intravenous dose of rApoAI-PBGDms, the protein was still detectable in the liver, and hepatic PBGD activity remained increased above control values. A long-lasting therapeutic effect of rApoAI-PBGDms was observed after either intravenous or subcutaneous administration.

These data describe a method to deliver PBGD to hepatocytes with resulting enhanced hepatic enzymatic activity and protection against AIP attacks in rodent models, suggesting that the approach might be an effective therapy for AIP.

ARTICLE CITATION  Sci Transl Med. 2022 Jan 12;14(627):eabc0700. doi: 10.1126/scitranslmed.abc0700.

Our authors

Karol Marcela Córdoba Quiñones
Irantzu Serrano Mendioroz
Daniel Jericó Asenjo
Ana Sampedro Pascual
Laboratory technician Porphyrias Research Group